Dr Timos Papagatsias retweeted
Are you interested in #GSK #CVC and investment portfolio?
Gain now 💡 insights into the 2023 📊 BioPharma (+ Google) Corporate Venture Capital Investment Trends ➡️ dlvr.it/SmgwNn
CVCs analyzed: #AbbVie Ventures, #Amgen Ventures, #Astellas… dlvr.it/SmgwP0
Dr Timos Papagatsias retweeted
Are you interested in #Google Ventures #CVC and investment portfolio?
Gain now 💡 insights into the 2023 📊 BioPharma (+ Google) Corporate Venture Capital Investment Trends ➡️ dlvr.it/Smg6PB
CVCs analyzed: #AbbVie Ventures, #Amgen Ventures,… dlvr.it/Smg6Ps
Dr Timos Papagatsias retweeted
Are you interested in #EMDSerono #CVC and investment portfolio?
Gain now 💡 insights into the 2023 📊 BioPharma (+ Google) Corporate Venture Capital Investment Trends ➡️ dlvr.it/SmfnSg
CVCs analyzed: #AbbVie Ventures, #Amgen Ventures,… dlvr.it/SmfnSv
LucidQuest Updates > RFU and Xcellerant Ventures: Jetstream Partnership | Lucid Diligence Brief dlvr.it/TW4Yjn #LucidDiligenceBrief #healthinnovation Comment below!
LucidQuest Updates > Immunology Strategic Roundup: Rising Evidence Standards | Sep 22—Oct 26, 2026 dlvr.it/TW4Xm7 #MonthlyStrategicRoundups #OurInsights Comment below!
Dr Timos Papagatsias retweeted
Are you interested in #Lilly Ventures #CVC and investment portfolio?
Gain now 💡 insights into the 2023 📊 BioPharma (+ Google) Corporate Venture Capital Investment Trends ➡️ dlvr.it/SmfJzP
CVCs analyzed: #AbbVie Ventures, #Amgen Ventures,… dlvr.it/SmfK0B
Dr Timos Papagatsias retweeted
Are you interested in #Boehringer Ingelheim #CVC and investment portfolio?
Gain now 💡 insights into the 2023 📊 BioPharma (+ Google) Corporate Venture Capital Investment Trends ➡️ dlvr.it/SmfC89
CVCs analyzed: #AbbVie Ventures, #Amgen… dlvr.it/SmfC8T
Dr Timos Papagatsias retweeted
Are you interested in #Bayer #CVC and investment portfolio?
Gain now 💡 insights into the 2023 📊 BioPharma (+ Google) Corporate Venture Capital Investment Trends ➡️ dlvr.it/Smdyh4
CVCs analyzed: #AbbVie Ventures, #Amgen Ventures, #Astellas… dlvr.it/SmdyhD
Dr Timos Papagatsias retweeted
Are you interested in #Astellas Ventures #CVC and investment portfolio?
Gain now 💡 insights into the 2023 📊 BioPharma (+ Google) Corporate Venture Capital Investment Trends ➡️ dlvr.it/SmdN0J
CVCs analyzed: #AbbVie Ventures, #Amgen… dlvr.it/SmdN0Y
Dr Timos Papagatsias retweeted
Are you interested in #Amgen Ventures #CVC and investment portfolio?
Gain now 💡 insights into the 2023 📊 BioPharma (+ Google) Corporate Venture Capital Investment Trends ➡️ dlvr.it/Smd7cV
CVCs analyzed: #AbbVie Ventures, #Amgen Ventures,… dlvr.it/Smd7dG
Dr Timos Papagatsias retweeted
Are you interested in #AbbVie Ventures #CVC and investment portfolio?
Gain now 💡 insights into the 2023 📊 BioPharma (+ Google) Corporate Venture Capital Investment Trends ➡️ dlvr.it/Smcw9t
CVCs analyzed: #AbbVie Ventures, #Amgen Ventures,… dlvr.it/SmcwB0
Dr Timos Papagatsias retweeted
Want to see what #Amgen and other companies do in the oncology / hematology space? ➡️ dlvr.it/SnG19n
#oncology #hematology #pharma #abbvie #amgen #astrazeneca #bms #gilead #gsk #janssen #merck #emdserono #lilly #novartis #pfizer #roche #takeda… dlvr.it/SnG1BR
Dr Timos Papagatsias retweeted
Want to see what #AbbVie and other companies do in the oncology / hematology space? ➡️ dlvr.it/Sm1nVl
#oncology #hematology #pharma #abbvie #amgen #astrazeneca #bms #gilead #gsk #janssen #merck #emdserono #lilly #novartis #pfizer #roche… dlvr.it/Sm1nVp
LucidQuest Updates > ESGCT 2026 Preview: Gene and Cell Therapy Trends dlvr.it/TW40VJ #ConferencePreviews #OurInsights #AAVmanufacturing Comment below!
LucidQuest Updates > AAN 2026 Preview: Emerging Neurology Trends and AI dlvr.it/TW3y3Z #ConferencePreviews #OurInsights #neurology Comment below!
1/6 🧬 #ESGCT2026 will put delivery, durability, safety and manufacturing scale under the spotlight.
Key competitive shifts: in vivo gene editing, in vivo CAR-T, differentiated AAV platforms and AI-enabled therapeutic design.
#LucidQuest's preview: bit.ly/4sohRm5 @ESGCT
5/6 🤖 AI/ML is expanding across capsid design, off-target prediction and bioprocessing.
Dyno, Lir, Basecamp and WhiteLab are among the companies to watch.
The strategic test: cross-species translation, manufacturing reproducibility and regulatory validation.
6/6 👀 Post-#ESGCT2026 watchpoints:
🧬 Clinical signals from ATA-200, ETX101 and AVB-406
🧫 AAV durability, hepatic safety and redosing
💸 Manufacturing economics and access
🔗 Explore LucidQuest's ESGCT 2026 preview: bit.ly/4sohRm5
[email protected]















